DOI 10.1016/j.annonc.2026.07.412
Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Аннотация
BACKGROUND
We previously reported that, at median follow-ups of 34 and 68 months, enzalutamide improved overall survival (OS) compared with a first-generation nonsteroidal antiandrogen (NSAA) when used with testosterone suppression for metastatic hormone-sensitive prostate cancer (mHSPC). We now report longer-term outcomes with a focus on adverse events (AEs) and causes of death.
PATIENTS AND
METHODS
Participants with mHSPC were randomly assigned (1 : 1) to receive daily enzalutamide or NSAA in addition to testosterone suppression; concurrent early docetaxel was permitted at clinician discretion. OS was the primary endpoint; secondary endpoints included progression-free survival (PFS), cause-specific survival, duration of treatment, and AEs.
RESULTS
At a median follow-up of 8.1 years (97 months), deaths occurred in 285 of 563 (51%) participants assigned enzalutamide versus 337 of 562 (60%) assigned NSAA. OS was longer with enzalutamide than with NSAA [median 7.9 versus 5.8 years; OS at 8 years 50% versus 40%; hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.63-0.86, P = 0.0001]. Clinical PFS at 8 years also favoured enzalutamide (43% versus 20%; HR 0.49, 95% CI 0.42-0.57, P < 0.0001). Of the 622 deaths, 468 were attributed to prostate cancer, of which fewer were associated with enzalutamide than with NSAA (207 versus 261), whereas deaths attributed to other causes occurred with similar frequency in the two groups (78 versus 76). Median treatment duration was 4.8 years with enzalutamide and 1.9 years with NSAA. Of 185 of 563 (33%) participants still receiving enzalutamide at data cut-off, most (163 of 185, 88%) remain on the full 160-mg dose. Rates of grade 3-5 AEs per 100 person-years were similar between groups for cardiac (2.2 versus 2.2) and nervous system disorders (2.3 versus 2.0), with more falls observed with enzalutamide (0.70 versus 0.24).
CONCLUSION
Enzalutamide continues to provide substantial long-term OS benefit at 8 years, with sustained efficacy, maintenance of full dose in most participants, and no increase in non-prostate cancer mortality.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.